Literature DB >> 6981688

Chronic arachnoiditis in the posterior fossa: a study of 82 cases.

Z Rongxun.   

Abstract

Arachnoiditis in the posterior fossa is not a rare disorder in China. Eighty-two cases seen in a three year period were studied with reference to symptomatology, aetiology and treatment. The presentation was contrasted with that of increased intracranial pressure caused by tumour. The efficacy of treatment by direct exploration and shunt surgery was emphasised.

Entities:  

Mesh:

Year:  1982        PMID: 6981688      PMCID: PMC491474          DOI: 10.1136/jnnp.45.7.598

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

1.  Follow-up analysis of ventriculoperitoneal and ventriculoatrial shunts for hydrocephalus.

Authors:  R J Ignelzi; W M Kirsch
Journal:  J Neurosurg       Date:  1975-06       Impact factor: 5.115

2.  Infratentorial arachnoid cysts.

Authors:  J R Little; M R Gomez; C S MacCarty
Journal:  J Neurosurg       Date:  1973-09       Impact factor: 5.115

3.  Arachnoid cyst of the cerebellopontine angle and infantile spastic hemiplegia. Case report.

Authors:  M R Gomez; T Yanagihara; C S MacCarty
Journal:  J Neurosurg       Date:  1968-07       Impact factor: 5.115

4.  Ventriculoperitoneal shunting for hydrocephalus.

Authors:  J S Robertson; M I Maraqa; B Jennett
Journal:  Br Med J       Date:  1973-05-05

5.  Long-term results after ventriculoatrial and ventriculoperitoneal shunting for infantile hydrocephalus.

Authors:  T R Keucher; J Mealey
Journal:  J Neurosurg       Date:  1979-02       Impact factor: 5.115

  5 in total
  1 in total

Review 1.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.